Xenetic Biosciences, Inc. released an updated investor presentation on September 23, 2026, detailing the terms of a proposed share exchange transaction with Santersus AG. The filing indicates that the transaction is structured as a share exchange agreement signed on September 14, 2026, and is pending completion.
According to the presentation, the transaction is valued at approximately $141 million for Santersus AG. In exchange, Xenetic will issue approximately 17,099,265 new shares of its common stock to Santersus shareholders. This issuance is based on an exchange ratio that converts Santersus shares into Xenetic stock.
Following the closing of the proposed transaction, the pro forma ownership structure of the combined company is estimated to be approximately 85.0% held by Xenetic shareholders and 15.0% held by Santersus shareholders. This calculation assumes that Xenetic will have approximately 14,552,566 shares outstanding after the issuance of new shares to Santersus.
Xenetic disclosed that it will file a Proxy Statement on Schedule 14A and a Registration Statement on Form S-1 with the SEC in connection with the acquisition. The company noted that investors are urged to read these documents carefully when they become available.
